Agios Pharmaceuticals, Inc. (AGIO): Price and Financial Metrics
AGIO Price/Volume Stats
| Current price | $29.43 | 52-week high | $35.50 |
| Prev. close | $29.03 | 52-week low | $19.80 |
| Day low | $29.03 | Volume | 549,500 |
| Day high | $29.90 | Avg. volume | 806,073 |
| 50-day MA | $29.33 | Dividend yield | N/A |
| 200-day MA | $25.44 | Market Cap | 1.65B |
AGIO Stock Price Chart Interactive Chart >
Agios Pharmaceuticals, Inc. (AGIO) Company Bio
Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Latest AGIO News From Around the Web
Below are the latest news stories about AGIOS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AGIO as an investment opportunity.
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Markers of Hemolysis and Erythropoiesis in Participants Treated with Mitapivat – – Agios to Host Live and Webcast Investor Event on Dec. 11, 2023, at 7:00 a.m. Pacific Time – CAMBRIDGE, Mass., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular |
Agios Pharmaceuticals (NASDAQ:AGIO) shareholders have endured a 59% loss from investing in the stock five years agoWe think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly... |
Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia TreatmentData from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint. |
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy Volunteers Study – – Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that clinical proof-of-concep |
Time To Worry? Analysts Just Downgraded Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) OutlookMarket forces rained on the parade of Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) shareholders today, when the analysts... |
AGIO Price Returns
| 1-mo | -2.65% |
| 3-mo | 35.43% |
| 6-mo | 37.65% |
| 1-year | 30.28% |
| 3-year | -47.14% |
| 5-year | -47.42% |
| YTD | 32.15% |
| 2023 | -20.69% |
| 2022 | -14.57% |
| 2021 | -24.14% |
| 2020 | -9.26% |
| 2019 | 3.56% |
Continue Researching AGIO
Want to see what other sources are saying about Agios Pharmaceuticals Inc's financials and stock price? Try the links below:Agios Pharmaceuticals Inc (AGIO) Stock Price | Nasdaq
Agios Pharmaceuticals Inc (AGIO) Stock Quote, History and News - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...